Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCardia, Inc. stock logo
BCDA
BioCardia
$1.08
-0.9%		$0.98
$0.75
▼
$2.29
$16.35M0.55188,730 shs57,265 shs
BioVie Inc. stock logo
BIVI
BioVie
$2.00
-1.5%		$1.73
$0.82
▼
$3.79
$16.90M0.7413.68 million shs282,792 shs
Bionomics Limited stock logo
BNOX
Bionomics
$0.25
$0.27
$0.18
▼
$0.94
$4.47M0.266.12 million shsN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$1.03
-1.9%		$1.02
$0.84
▼
$12.23
$17.37M-1.68298,356 shs214,634 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCardia, Inc. stock logo
BCDA
BioCardia
-0.92%-6.09%+13.68%+4.85%-47.06%
BioVie Inc. stock logo
BIVI
BioVie
-1.48%-7.41%-1.96%+25.00%+19.76%
Bionomics Limited stock logo
BNOX
Bionomics
0.00%0.00%0.00%0.00%0.00%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-1.90%-2.83%+12.65%-18.90%-90.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCardia, Inc. stock logo
BCDA
BioCardia
$1.08
-0.9%		$0.98
$0.75
▼
$2.29
$16.35M0.55188,730 shs57,265 shs
BioVie Inc. stock logo
BIVI
BioVie
$2.00
-1.5%		$1.73
$0.82
▼
$3.79
$16.90M0.7413.68 million shs282,792 shs
Bionomics Limited stock logo
BNOX
Bionomics
$0.25
$0.27
$0.18
▼
$0.94
$4.47M0.266.12 million shsN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$1.03
-1.9%		$1.02
$0.84
▼
$12.23
$17.37M-1.68298,356 shs214,634 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCardia, Inc. stock logo
BCDA
BioCardia
-0.92%-6.09%+13.68%+4.85%-47.06%
BioVie Inc. stock logo
BIVI
BioVie
-1.48%-7.41%-1.96%+25.00%+19.76%
Bionomics Limited stock logo
BNOX
Bionomics
0.00%0.00%0.00%0.00%0.00%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-1.90%-2.83%+12.65%-18.90%-90.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCardia, Inc. stock logo
BCDA
BioCardia
2.00
Hold$25.002,214.81% Upside
BioVie Inc. stock logo
BIVI
BioVie
1.00
SellN/AN/A
Bionomics Limited stock logo
BNOX
Bionomics
0.00
N/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest BNOX, TPST, BIVI, and BCDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/11/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
7/17/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
BioVie Inc. stock logo
BIVI
BioVie
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/13/2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/13/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/9/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$25.00
(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/A$0.18 per shareN/A
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/A$1.22 per shareN/A
Bionomics Limited stock logo
BNOX
Bionomics
$10K446.82N/AN/A$1.32 per share0.19
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCardia, Inc. stock logo
BCDA
BioCardia
-$8.23M-$0.64N/AN/AN/AN/A-569.36%-183.15%11/11/2026 (Estimated)
BioVie Inc. stock logo
BIVI
BioVie
-$22.07M-$3.15N/AN/AN/AN/A-126.02%-108.88%11/9/2026 (Estimated)
Bionomics Limited stock logo
BNOX
Bionomics
-$15.49MN/AN/AN/AN/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$26.26M-$4.28N/AN/AN/AN/A-576.56%-134.99%11/4/2026 (Estimated)

Latest BNOX, TPST, BIVI, and BCDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$0.30-$0.34-$0.04-$0.34N/AN/A
8/12/2026Q2 2026
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.18-$0.13+$0.05-$0.13N/AN/A
8/12/2026Q4 2026
BioVie Inc. stock logo
BIVI
BioVie
-$0.52-$0.70-$0.18-$0.70N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/AN/A
Bionomics Limited stock logo
BNOX
Bionomics
N/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
2.09
2.09
BioVie Inc. stock logo
BIVI
BioVie
N/A
3.59
3.59
Bionomics Limited stock logo
BNOX
Bionomics
N/A
3.30
3.30
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
0.38
0.38

Institutional Ownership

CompanyInstitutional Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
BioVie Inc. stock logo
BIVI
BioVie
4.59%
Bionomics Limited stock logo
BNOX
Bionomics
15.90%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%

Insider Ownership

CompanyInsider Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
17.40%
BioVie Inc. stock logo
BIVI
BioVie
0.90%
Bionomics Limited stock logo
BNOX
Bionomics
0.69%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
36.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCardia, Inc. stock logo
BCDA
BioCardia
4015.14 million12.51 millionOptionable
BioVie Inc. stock logo
BIVI
BioVie
108.45 million8.38 millionNo Data
Bionomics Limited stock logo
BNOX
Bionomics
N/A17.65 million17.53 millionNot Optionable
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
2016.54 million10.55 millionNo Data

Recent News About These Companies

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors
August 13, 2026  |  quiverquant.comQ
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344974/0/en/tempest-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69081647-tempest-therapeutics-tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-399.htm
Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases
July 21, 2026  |  quiverquant.comQ
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330290/0/en/tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-t.html
Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial
July 15, 2026  |  quiverquant.comQ
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327582/0/en/tempest-unveils-next-generation-in-vivo-car-t-pipeline-with-first-clinical-study-planned-for-the-fourth-quarter-of-2026.html
Tempest Therapeutics, Inc. Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026  |  quiverquant.comQ
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3307117/0/en/tempest-therapeutics-appoints-drake-richey-and-john-yee-md-mph-to-board-of-directors.html
Tempest Therapeutics Announces Resignation of Board Director
May 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tempest-therapeutics-announces-resignation-of-board-director?utm_source=marketbeat.com&utm_medium=referral
Tempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term Warrants
May 29, 2026  |  quiverquant.comQ
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
May 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/29/3303540/0/en/tempest-therapeutics-announces-warrant-exercise-for-approximately-2-million-in-gross-proceeds.html
Tempest Therapeutics Announces Multiple Board Director Resignations
May 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tempest-therapeutics-announces-multiple-board-director-resignations?utm_source=marketbeat.com&utm_medium=referral
Tempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68505685-tempest-therapeutics-tempest-reports-first-quarter-2026-financial-results-and-provides-business-update-399.htm
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3295395/0/en/tempest-reports-first-quarter-2026-financial-results-and-provides-business-update.html
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288654/0/en/tempest-presents-clinical-update-at-isct-2026-annual-meeting.html
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283678/0/en/tempest-to-advance-dual-targeting-car-t-platform-with-clinical-update-at-isct-2026-annual-meeting.html
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3278911/0/en/tempest-announces-key-manufacturing-milestone-for-tpst-2003-dual-targeting-cd19-bcma-car-t.html
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
April 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/14/3273302/0/en/tempest-appoints-andrew-fang-ph-d-as-head-of-business-development-to-advance-strategic-partnerships-and-global-licensing-efforts.html
New Strong Buy Stocks for April 10th
April 10, 2026  |  zacks.comhttps://www.zacks.com/commentary/2897019/new-strong-buy-stocks-for-april-10th

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCardia stock logo

BioCardia NASDAQ:BCDA

$1.08 -0.01 (-0.92%)
As of 09/4/2026 04:00 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

BioVie stock logo

BioVie NASDAQ:BIVI

$2.00 -0.03 (-1.48%)
As of 09/4/2026 04:00 PM Eastern

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Bionomics stock logo

Bionomics NASDAQ:BNOX

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$1.03 -0.02 (-1.90%)
As of 09/4/2026 04:00 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas